Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Mar 21, 2023; 29(11): 1745-1756
Published online Mar 21, 2023. doi: 10.3748/wjg.v29.i11.1745
Published online Mar 21, 2023. doi: 10.3748/wjg.v29.i11.1745
Outcomes of ABO-incompatible liver transplantation in end-stage liver disease patients co-infected with hepatitis B and human immunodeficiency virus
Jian-Xin Tang, Kang-Jun Zhang, Tai-Shi Fang, Zi-Ming Liang, Xu Yan, Xin Jin, Lin-Jie Xie, Xin-Chen Zeng, Dong Zhao, Department of Liver Surgery and Organ Transplantation Center, The Third People's Hospital of Shenzhen (The Second Affiliated Hospital of Southern University of Science and Technology), Shenzhen 518000, Guangdong Province, China
Rui-Hui Weng, Department of Neurology, The Third People’s Hospital of Shenzhen (The Second Affiliated Hospital of Southern University of Science and Technology), Shenzhen 518000, Guangdong Province, China
Dong Zhao, Department of Liver Surgery and Organ Transplantation Center, National Clinical Research Center for Infectious Disease, Shenzhen 518000, Guangdong Province, China
Author contributions: Zhao D and Tang JX performed the conception and design; Zhao D contributed to the administrative support; Tang JX, Zhang KJ and Fang TS contributed to the provision of study materials or patients; Liang ZM, Yan X, Jin X and Zeng XC performed the collection and assembly of data; Weng RH and Xie LJ contributed to the data analysis and interpretation; All authors participated in the writing and final approval of the manuscript.
Supported by The Third People's Hospital of Shenzhen Scientific Research Project , No. G2021008 and No. G2022008 ; Shenzhen Key Medical Discipline Construction Fund , No. SZXK079 ; Shenzhen Science and Technology Research and Development Fund , No. JCYJ20210324131809027 and No. JCYJ20220530163011026 .
Institutional review board statement: The study was approved by ethics committee of the Third People's Hospital of Shenzhen, No. 2022-038-02.
Informed consent statement: All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrollment.
Conflict-of-interest statement: All the authors report having no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Dong Zhao, MD, Chief Doctor, Professor, Surgeon, Department of Liver Surgery and Organ Transplantation Center, The Third People's Hospital of Shenzhen, No. 29 Bulan Road, Longgang District, Shenzhen 518000, Guangdong Province, China. zdong1233@126.com
Received: October 24, 2022
Peer-review started: October 24, 2022
First decision: November 2, 2022
Revised: November 7, 2022
Accepted: March 6, 2023
Article in press: March 6, 2023
Published online: March 21, 2023
Peer-review started: October 24, 2022
First decision: November 2, 2022
Revised: November 7, 2022
Accepted: March 6, 2023
Article in press: March 6, 2023
Published online: March 21, 2023
Core Tip
Core Tip: The outcome of human immunodeficiency virus (HIV)-hepatitis B virus (HBV) coinfected patients referred for ABO-incompatible liver transplantation (LT) (ABOi-LT) is unknown. We report on two Chinese HIV-HBV coinfected patients with end-stage liver disease (ESLD) who underwent A to O brain-dead donor LT and reviewed the literature on HIV-HBV coinfected patients treated with ABO-compatible LT. At intermediate-term follow-up, patients showed undetectable HIV viral load, CD4(+) T cell counts greater than 150 cells/μL, no HBV recurrence, and stable liver function. Both patients survived at 36-42 mo of follow-up. This is the first report of ABOi-LT in HIV-HBV recipients with good intermediate-term outcomes, suggesting that ABOi-LT may be feasible and safe for HIV-HBV coinfected patients with ESLD.